Bicycle Therapeutics (NASDAQ:BCYC – Get Rating) released its quarterly earnings data on Thursday. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05), Fidelity Earnings reports. Bicycle Therapeutics had a negative net margin of 568.71% and a negative return on equity of 31.61%.
Bicycle Therapeutics Stock Performance
Shares of NASDAQ BCYC traded up $0.84 during trading on Friday, hitting $26.20. The company had a trading volume of 422,437 shares, compared to its average volume of 413,918. The stock has a 50 day simple moving average of $18.41 and a 200 day simple moving average of $30.08. The firm has a market capitalization of $776.80 million, a P/E ratio of -9.07 and a beta of 0.76. Bicycle Therapeutics has a 12 month low of $12.08 and a 12 month high of $62.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 12.14 and a current ratio of 12.14.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on BCYC shares. TheStreet cut Bicycle Therapeutics from a “c-” rating to a “d+” rating in a research report on Thursday, April 21st. JMP Securities reaffirmed a “buy” rating and set a $70.00 price objective on shares of Bicycle Therapeutics in a research report on Monday, June 6th. SVB Leerink dropped their price objective on Bicycle Therapeutics from $69.00 to $48.00 and set an “outperform” rating on the stock in a research report on Friday. HC Wainwright dropped their target price on Bicycle Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research report on Friday. Finally, B. Riley cut Bicycle Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $62.00 to $33.00 in a research report on Wednesday, April 13th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, Bicycle Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $56.92.
Institutional Trading of Bicycle Therapeutics
About Bicycle Therapeutics
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
- Get a free copy of the StockNews.com research report on Bicycle Therapeutics (BCYC)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.